Medtronic unveils SynchroMed advance in US:
This article was originally published in Clinica
Executive Summary
Medtronic is to launch an extended life version of its SynchroMed implantable drug delivery system in the US market. The device has been used since 1988 to treat cancer and non-malignant chronic pain and to deliver drugs directly into fluid surrounding the spinal cord. The extended life version claims to extend the battery life of the system from four to seven years, with the capability of lower flow rates in order to use the device for a wider range of drugs.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.